Cover Image
Market Research Report

Global Hyperkalemia Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 759912
Published Content info 106 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Hyperkalemia Drugs Market 2019-2023
Published: December 7, 2018 Content info: 106 Pages
Description

About this market:

The growing cases of various chronic diseases such as chronic kidney diseases and cardiovascular- related disorders are driving the market growth. Chronic kidney diseases increase the risk of patient developing hyperkalemia significantly, as the kidneys lose the ability to excrete potassium through urine. The ability of kidneys to excrete potassium decreases with time, which increases the risk of hyperkalemia becoming acute. Similarly, cardiovascular- related disorders also increase the risk of hyperkalemiain people. Hence, the increasing prevalence of these diseases is expected to contribute heavily of the growth of the market during the forecast. The hyperkalemia drugs market will grow at a CAGR of more than 20% during the forecast period.

Market Overview:

Increasing prevalence of hyperkalemia

The global hyperkalemia drugs market has witnessed a growth in recent years, primarily due to the increasing prevalence of the disease globally. The recurring nature of the disease is another factor that is expected to contribute to the huge unmet need globally. Due to the increasing prevalence and the huge unmet need, the market has witnessed the approval of novel drugs.

Lack of approved therapies

The treatment using these therapies is known to decrease the potassium levels in the blood only to a certain extent. Due to the presence of a limited number of approved therapies, the market has huge growth potential; however the pipeline for hyperkalemia is weak, with only two molecules bring studied currently. These molecules are in the pre- clinical stages of development and are not expected to enter the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the hyperkalemia drugs market during the 2019-2023, view our report.

Competitive Landscape:

The global hyperkalemia drugs market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.'

Table of Contents
Product Code: IRTNTR30460

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Chronic hyperkalemia - Market size and forecast 2018-2023
  • Acute hyperkalemia - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global urological disorder drugs market
  • Exhibit 03: Segments of global urological disorder drugs market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Chronic hyperkalemia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Chronic hyperkalemia - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Acute hyperkalemia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Acute hyperkalemia - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Key leading countries
  • Exhibit 35: Market opportunity
  • Exhibit 36: Decision framework
  • Exhibit 37: Impact of drivers and challenges
  • Exhibit 38: Vendor landscape
  • Exhibit 39: Landscape disruption
  • Exhibit 40: Vendors covered
  • Exhibit 41: Vendor classification
  • Exhibit 42: Market positioning of vendors
  • Exhibit 43: Ardelyx - Vendor overview
  • Exhibit 44: Ardelyx - Business segments
  • Exhibit 45: Ardelyx - Organizational developments
  • Exhibit 46: Ardelyx - Geographic focus
  • Exhibit 47: Ardelyx - Key offerings
  • Exhibit 48: Ardelyx - Key customers
  • Exhibit 49: AstraZeneca - Vendor overview
  • Exhibit 50: AstraZeneca - Business segments
  • Exhibit 51: AstraZeneca - Organizational developments
  • Exhibit 52: AstraZeneca - Geographic focus
  • Exhibit 53: AstraZeneca - Key offerings
  • Exhibit 54: AstraZeneca - Key customers
  • Exhibit 55: Perrigo - Vendor overview
  • Exhibit 56: Perrigo - Business segments
  • Exhibit 57: Perrigo - Organizational developments
  • Exhibit 58: Perrigo - Geographic focus
  • Exhibit 59: Perrigo - Segment focus
  • Exhibit 60: Perrigo - Key offerings
  • Exhibit 61: Perrigo - Key customers
  • Exhibit 62: Sanofi - Vendor overview
  • Exhibit 63: Sanofi - Business segments
  • Exhibit 64: Sanofi - Organizational developments
  • Exhibit 65: Sanofi - Geographic focus
  • Exhibit 66: Sanofi - Segment focus
  • Exhibit 67: Sanofi - Key offerings
  • Exhibit 68: Sanofi - Key customers
  • Exhibit 69: Vifor Pharma - Vendor overview
  • Exhibit 70: Vifor Pharma - Business segments
  • Exhibit 71: Vifor Pharma - Organizational developments
  • Exhibit 72: Vifor Pharma - Geographic focus
  • Exhibit 73: Vifor Pharma - Key offerings
  • Exhibit 74: Vifor Pharma - Key customers
  • Exhibit 75: Validation techniques employed for market sizing
  • Exhibit 76: List of abbreviations
Back to Top